NCT05288153 is a Phase 4 clinical trial of Metformin in Gastric Intestinal Metaplasia, sponsored by Xijing Hospital of Digestive Diseases.

Who is sponsoring NCT05288153?

NCT05288153 is sponsored by Xijing Hospital of Digestive Diseases.

What drugs are being tested in NCT05288153?

Interventions in NCT05288153: Metformin, Folate.

What condition does NCT05288153 study?

NCT05288153 studies Gastric Intestinal Metaplasia.

Is NCT05288153 still recruiting?

NCT05288153 is currently completed. Last updated 23 September 2024.

Last reviewed 2024-09-23 · How we verify

NCT05288153

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin Efficacy and Safety for Gastric Intestinal Metaplasia

Completed Phase 4 Last updated 23 September 2024

What this trial tests

Phase 4 trial testing Metformin in Gastric Intestinal Metaplasia in 140 participants. Completed in 31 October 2023.

Timeline

1 April 2022

Primary endpoint
31 May 2023

31 October 2023

Quick facts

Lead sponsor	Xijing Hospital of Digestive Diseases
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	140
Start date	1 April 2022
Primary completion	31 May 2023
Estimated completion	31 October 2023
Sites	2 locations across China

Drugs / interventions tested

Metformin (metformin) — full drug profile →
Folate — full drug profile →

Conditions studied

Gastric Intestinal Metaplasia — all drugs for Gastric Intestinal Metaplasia →

Sponsor

Xijing Hospital of Digestive Diseases

Who can join

Adults 18 to 75, any sex, with Gastric Intestinal Metaplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Gastric intestinal metaplasia significantly increases the risk of gastric cancer. Metformin, a biguanide, which is widely used for treating diabetes mellitus, has recently been suggested to have a suppressive effect on tumorigenesis and cancer cell growth. The investigators devised a prospective randomized controlled trial to evaluate the chemopreventive effect of metformin against gastric intestinal metaplasia and the safety of this drug in non-diabetic gastric intestinal metaplasia patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Therapeutic effect of metformin on reversing gastric intestinal metaplasia.
Li S, Li X, Zhu X, Zhao X, et al · · 2025 · cited 1× · PMID 40518567 · DOI 10.1097/cm9.0000000000003675

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Gastric Intestinal Metaplasia

Currently open trials in the same condition.

NCT06590454 — REVerse Intestinal Metaplasia in the Stomach (REVISE) · Phase 2 · recruiting
NCT06610266 — Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia · Phase 4 · recruiting
NCT06610760 — Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia · Phase 4 · recruiting
NCT06370143 — A Study Collecting Health Information to Understand and Prevent Gastric Cancer · recruiting
NCT05657080 — Cytosponge for Gastric Intestinal Metaplasia · recruiting

Other Xijing Hospital of Digestive Diseases trials

Trials by the same sponsor.

NCT07401303 — Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time · NA · not yet recruiting
NCT07296458 — FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy · Phase 3 · recruiting
NCT07129460 — Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia · Phase 4 · not yet recruiting
NCT07182890 — Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
NCT07187492 — Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05288153 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital of Digestive Diseases
Last refreshed: 23 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05288153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing